The CO-ANNEXIN study; assessing the efficacy and safety of ANXV (recombinant Annexin A5) in moderate tosevere COVID-19. De CO-ANNEXIN studie; onderzoek naar de effectiviteit en veiligheid van ANXV (recombinant Annexine A5) inmatig tot ernstige COVID-19.

ANXV - Annexin

Dec 30, 2021